chymotrypsin like elastase 3BGenealiases: CBPP · ELA3B
Q-omics provides the consensus-scored CELA3B profile across patient tissues and cancer cell-line models. CELA3B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CELA3B is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, CELA3B RNA expression shows 7,855 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight THCA, COAD, and PDAC as cancer lineages where CELA3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CELA3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CELA3B survival associations across molecular data types. CELA3B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CELA3B RNA expression–survival associations across cancer types. High CELA3B expression shows unfavorable associations in THCA, ACC, LIHC, KICH, SKCM and SCLC. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for CELA3B RNA expression.
This table summarizes CELA3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for CELA3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CELA3B shows lower tumor expression in COAD, STAD and READ and higher tumor expression in HNSC, LIHC and LUSC. The COAD box plot shows higher CELA3B RNA expression in normal versus tumor tissue (log2 FC = −0.628, t-test p < 0.001).
This table shows molecular features associated with CELA3B in patient tissues and cancer cell lines. In patient samples, CELA3B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CELA3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_NSCLC_LUAD.
